Table 5.
Weighted relative risk ratios (95% CIs) for sleep duration (reference, 7–<9 h/night) across quartiles of pyridoxal 5′-phosphate (PLP) concentrations (NHANES 2005–2010).
| Pyridoxal 5′-Phosphate (PLP) (nmol/L) | Model 2 a | ||
|---|---|---|---|
| Very Short Sleep (<5 h/Night) |
Short Sleep (5–<7 h/Night) |
Long Sleep (≥9 h/Night) |
|
| Q1 (<26.4) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Q2 (26.4 to <43.4) | 0.73 (0.54–1.00) | 0.79 (0.68–0.92) ** | 0.83 (0.53–1.30) |
| Q3 (43.4 to <74.8) | 0.58 (0.45–0.76) ** | 0.74 (0.65–0.85) ** | 0.62 (0.34–0.94) * |
| Q4 (≥74.8) | 0.58 (0.43–0.81) ** | 0.71 (0.61–0.83) ** | 0.67 (0.40–1.02) |
Calculated using multinomial logistic regression models. a Model 2 adjusted for age, sex, race/ethnicity, education level, household poverty ratio, marital status, body mass index, physical activity, smoking status, caffeine intake, energy, alcohol consumption, hypertension, diabetes, depressive symptoms, and sampling season. * p < 0.05; ** p < 0.01.